More U.S. Investors Join Arbitration Against South Korea Over Coupang Dispute 
FTC Questions Apple News Over Alleged Bias Against Conservative Media 
Air New Zealand Cabin Crew Strike Set for February 12–13 Amid Failed Talks 
Cloudflare Forecasts Strong Revenue Growth as AI Fuels Cloud Services Demand 
Converse Cuts Corporate Jobs as Nike Restructures to Revive Sales Growth 
Ancora Holdings Builds $200M Stake in Warner Bros Discovery, Targets Netflix Asset Sale Plan 
ANZ Shares Hit Record High After Strong Q1 Profit and Cost-Cutting Gains 
Gates Foundation Denies Financial Ties to Jeffrey Epstein Following DOJ Email Release 
Russia Signals Further Restrictions on Telegram Amid Ongoing Regulatory Disputes 
Novocure Stock Surges 30% After FDA Approves Optune Pax for Pancreatic Cancer Treatment 
U.S. Commerce Department Reaches $252 Million Settlement With Applied Materials Over China Exports 
Michael Kors Marks 45 Years at New York Fashion Week with Fall/Winter Collection Showcase 
Instagram CEO Defends Platform in Youth Mental Health Lawsuit Over Social Media Addiction Claims 
Xiaomi EV Deliveries Surpass 600,000 Units as SU7 and YU7 Drive Strong Growth 
CBA Shares Surge After Record Half-Year Profit as Rate Outlook Improves 
FAA Confirms $1.5 Billion Peraton Contract as U.S. Air Traffic Control Overhaul Accelerates 
NEWTON, Mass., Jan. 03, 2018 -- Acer Therapeutics Inc. (Nasdaq:ACER), a pharmaceutical company focused on the acquisition, development and commercialization of therapies for serious rare and ultra-rare diseases with critical unmet medical need, today announced that Chris Schelling, CEO and Founder, will provide a corporate overview at the Biotech Showcase™ Conference, being held January 8-10, 2018 in San Francisco.
Acer Therapeutics Conference Presentation Details
Date: Wednesday, January 10
Time: 1:30 pm Eastern Time (10:30 am Pacific Time)
Location: Hilton Union Square, Yosemite -B
Webcast: https://acertx.com/investor-relations/events-presentations/
About Acer Therapeutics
Acer, headquartered in Newton, MA, is a pharmaceutical company focused on the acquisition, development and commercialization of therapies for patients with serious rare and ultra-rare diseases with critical unmet medical need. Acer’s late-stage clinical pipeline includes two candidates for severe genetic disorders for which there are few or no FDA-approved treatments: EDSIVO™ (celiprolol) for vEDS, and ACER-001 (a fully taste-masked, immediate release formulation of sodium phenylbutyrate) for urea cycle disorders (UCD) and Maple Syrup Urine Disease (MSUD). There are no FDA-approved drugs for vEDS and MSUD and limited options for UCD, which collectively impact more than 4,000 patients in the United States. Acer’s product candidates have clinical proof-of-concept and mechanistic differentiation, and Acer intends to seek approval for them in the U.S. by using the regulatory pathway established under section 505(b)(2) of the Federal Food, Drug, and Cosmetic Act, or FFDCA, that allows an applicant to rely for approval at least in part on third-party data, which is expected to expedite the preparation, submission, and potential approval of a marketing application.
For more information, visit www.acertx.com.
Investor Contact:
Hans Vitzthum
LifeSci Advisors
Ph: 617-535-7743
[email protected]
